Bacterial Resistance Mechanisms

Intrinsic resistance is the natural insensitivity of a bacterial species to an antibiotic class, present in every member of the species regardless of prior antibiotic exposure. No selective pressure is required for it to be expressed. Classic examples include the resistance of Gram-negative bacteria to vancomycin (which cannot penetrate the outer membrane), the resistance of Pseudomonas aeruginosa to many penicillins due to limited outer membrane permeability combined with constitutive efflux pump expression, and the resistance of Enterococcus faecalis to all cephalosporins. Intrinsic resistance is predictable and stable; susceptibility testing is not required for drug-organism combinations known to exhibit it.

Acquired resistance arises in previously susceptible organisms through spontaneous chromosomal mutation or acquisition of foreign DNA carrying resistance determinants. When antibiotic concentrations kill susceptible bacteria but not a rare pre-existing resistant mutant, the mutant is selectively amplified. Antibiotics therefore select for resistance rather than cause it — a distinction that is mechanistically important. Prolonged subtherapeutic antibiotic concentrations are particularly prone to selecting for resistant mutants, because they kill susceptible organisms while allowing partially resistant variants to survive and undergo further mutational selection.

Horizontal gene transfer is the primary driver of the modern global resistance crisis. It operates through three mechanisms: conjugation (direct cell-to-cell transfer of plasmids via a pilus), transformation (uptake of free DNA from lysed bacteria), and transduction (bacteriophage-mediated DNA transfer). Conjugation is the most clinically important. Plasmids are extrachromosomal DNA elements that replicate independently and can carry multiple resistance genes, enabling co-transfer of resistance to several antibiotic classes in a single event — which explains why multidrug-resistant organisms frequently emerge with simultaneous resistance to multiple structurally unrelated drug classes.

Mobile genetic elements accelerate gene spread. Transposons carry resistance genes between chromosomes and plasmids. Integrons capture resistance gene cassettes through site-specific recombination and are strongly associated with clinical multidrug resistance. The combined action of these elements explains how resistance genes from environmental bacteria or livestock can appear rapidly in human pathogens worldwide.

Beta-lactamases hydrolyze the beta-lactam ring, destroying antibacterial activity. Narrow-spectrum beta-lactamases hydrolyze penicillins and early cephalosporins but not extended-spectrum cephalosporins or carbapenems. Extended-spectrum beta-lactamases (ESBLs), which arose through mutations, hydrolyze most penicillins, all cephalosporin generations including ceftriaxone and ceftazidime, and aztreonam — but not carbapenems. ESBL-producing organisms, predominantly Escherichia coli and Klebsiella pneumoniae, are defined by susceptibility to carbapenems and inhibition by classical beta-lactamase inhibitors such as clavulanic acid and tazobactam.

AmpC beta-lactamases are inducible cephalosporinases that resist inhibition by classical inhibitors. Organisms with inducible AmpC — including Enterobacter, Serratia, Citrobacter freundii, Acinetobacter, and Pseudomonas aeruginosa — can develop high-level resistance during therapy with third-generation cephalosporins through selection of mutants that constitutively overproduce the enzyme. This is why third-generation cephalosporins are avoided for serious infections caused by these organisms even when initial susceptibility is reported.

Carbapenemases hydrolyze carbapenems and eliminate the last reliable option for many multidrug-resistant Gram-negative infections. The major families are KPC (Klebsiella pneumoniae carbapenemase, most prevalent in the United States), NDM (New Delhi metallo-beta-lactamase, predominant in South Asia and now global), OXA-48 (prevalent in Europe and the Middle East), and other metallo-beta-lactamases. Metallo-beta-lactamases (including NDM) uniquely resist all currently available serine-targeted beta-lactamase inhibitors — notably, aztreonam combined with avibactam retains activity against many metallo-beta-lactamase producers because aztreonam is not hydrolyzed by metallo-beta-lactamases.

Aminoglycoside-modifying enzymes modify the aminoglycoside molecule through acetylation, phosphorylation, or adenylylation, reducing or abolishing its ability to bind the 16S ribosomal ribonucleic acid of the 30S subunit. The specific aminoglycoside affected depends on the enzyme type and modification site — for example, some enzymes confer resistance to gentamicin but not amikacin, which explains why amikacin often retains activity against gentamicin-resistant organisms. Chloramphenicol acetyltransferase inactivates chloramphenicol; this is the primary mechanism of clinical chloramphenicol resistance.

Beta-lactam antibiotics exert bactericidal activity by binding covalently to penicillin-binding proteins (PBPs), the transpeptidase enzymes responsible for cross-linking peptidoglycan. Methicillin-resistant Staphylococcus aureus resistance is mediated by the mecA gene, which encodes an alternative PBP designated PBP2a. PBP2a has greatly reduced affinity for all conventional beta-lactam antibiotics — while all other PBPs are occupied and inhibited by the drug, PBP2a continues to perform transpeptidation, enabling cell wall synthesis to proceed. The mecA gene is carried on a mobile genetic element integrated into the staphylococcal chromosome; different variants are associated with hospital-acquired and community-acquired methicillin-resistant Staphylococcus aureus strains.

Ceftaroline is the first beta-lactam with sufficient affinity for PBP2a to retain activity against methicillin-resistant Staphylococcus aureus, through greater affinity for PBP2a than conventional beta-lactams.

Vancomycin resistance in enterococci is a target bypass mechanism. Vancomycin binds the D-alanyl-D-alanine terminus of the peptidoglycan precursor. Vancomycin-resistant enterococcus resistance, mediated primarily by the vanA and vanB gene clusters, reprograms cell wall biosynthesis to produce a precursor terminating in D-alanyl-D-lactate instead of D-alanyl-D-alanine. Vancomycin has approximately 1,000-fold lower affinity for the D-alanyl-D-lactate terminus, rendering it essentially ineffective. The vanA cluster confers high-level resistance to both vancomycin and teicoplanin and is transferable by conjugation. The vanB cluster confers variable resistance to vancomycin but not to teicoplanin. Transfer of vanA from vancomycin-resistant enterococcus to methicillin-resistant Staphylococcus aureus produces vancomycin-resistant Staphylococcus aureus — one of the most feared potential resistance developments in clinical infectious disease.

The erm gene family encodes methyltransferases that methylate the ribosomal binding site. This single methylation event simultaneously confers resistance to macrolides, lincosamides, and streptogramin B — the macrolide-lincosamide-streptogramin B phenotype. As noted in Module 10, erm expression can be constitutive (detectable by standard susceptibility testing) or inducible (appearing susceptible on routine testing but causing treatment failure with clindamycin, detectable by the D-zone test). Tetracycline resistance by ribosomal protection involves proteins that displace tetracycline from the ribosomal A-site, allowing translation to resume.

Fluoroquinolone resistance through target modification involves point mutations in the genes encoding DNA gyrase and topoisomerase IV, the two enzyme complexes targeted by fluoroquinolones. Single mutations in the primary target typically produce low- to moderate-level resistance; high-level resistance requires additional mutations in both primary and secondary targets. Because mutations in two independent genes must occur simultaneously for high-level resistance, fluoroquinolones can select for resistance through sequential single-step mutations during prolonged courses, with each mutation conferring incremental increases in minimum inhibitory concentration until the organism reaches clinical resistance.

Bacterial efflux pumps are membrane transport proteins that actively extrude antibiotics from the bacterial cell interior. In Gram-negative bacteria, major efflux systems span both the inner and outer membranes, extruding drugs directly into the extracellular environment. These pumps simultaneously efflux fluoroquinolones, beta-lactams, tetracyclines, and chloramphenicol. Overexpression of these pumps through regulatory gene mutations is one of the most common mechanisms of fluoroquinolone resistance and simultaneously elevates resistance to multiple drug classes — producing multidrug resistance without any resistance gene acquisition.

Porins are outer membrane channel proteins through which hydrophilic antibiotics — including beta-lactams, fluoroquinolones, and carbapenems — diffuse into the periplasm of Gram-negative bacteria. Loss of specific porins through mutation significantly reduces antibiotic entry; when combined with efflux pump overexpression, porin loss produces synergistic resistance increases far exceeding what either mechanism alone confers. Loss of porins combined with extended-spectrum beta-lactamase or AmpC production is a mechanism of carbapenem resistance in organisms without a carbapenemase gene. In Pseudomonas aeruginosa, loss of a specific outer membrane porin combined with efflux overexpression produces selective imipenem resistance while meropenem may retain activity — explaining the clinical phenomenon of imipenem-resistant but meropenem-susceptible Pseudomonas aeruginosa.

The epidemiology of resistance gene spread is best understood through successful plasmid-organism combinations that have spread globally. A globally disseminated lineage of Escherichia coli, which carries extended-spectrum beta-lactamase genes and is fluoroquinolone-resistant through chromosomal mutations, has become the dominant cause of community-onset ESBL-producing urinary tract infection in many countries without any link to healthcare exposure. Similarly, a specific Klebsiella pneumoniae lineage carrying KPC carbapenemases has established itself in healthcare institutions across multiple continents. These high-risk clones combine multiple resistance mechanisms with fitness attributes that enable prolonged silent colonization and transmission.

Agricultural antibiotic use creates selection pressure in animal gut flora that accelerates transfer and amplification of resistance genes subsequently transmissible to human pathogens through the food chain, water, and direct animal contact. The One Health framework, recognizing the interdependence of human, animal, and environmental health in resistance epidemiology, has become the dominant conceptual framework for global resistance control policy.